Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

Adagene Inc.

CIK 1818838Updated Nov 20, 2026

ADAG price & chart

Provider market data

Loading TradingView…

NASDAQ:ADAG on TradingView ↗

TradingView · Data may be delayed

About the company

Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science.

6-K · 2026-11-19 · 0001104659-26-129932

Company description from the cited filing.

In the news

No coverage from other publishers is available.

Seeking Alpha

Recent filings

  1. 6-K filing

    6-K · 2026-11-19 · 0001104659-26-129932

  2. 6-K filing

    6-K · 2026-11-17 · 0001104659-26-128842

  3. 6-K filing

    6-K · 2026-11-09 · 0001104659-26-124143

  4. 6-K filing

    6-K · 2026-09-25 · 0001104659-26-110982

  5. 6-K filing

    6-K · 2026-09-22 · 0001104659-26-109485

Show 5 more recent filings
  1. 6-K filing

    6-K · 2026-09-10 · 0001104659-26-106554

  2. 6-K filing

    6-K · 2026-09-09 · 0001104659-26-106137

  3. 144/A filing

    144/A · 2026-08-20 · 0001104659-26-099289

  4. 144 filing

    144 · 2026-08-19 · 0002108105-26-000001

  5. 4 filing

    4 · 2026-08-18 · 0001104659-26-098426

Financials

FY 2025 · USD
Revenue7,670,902USD · FY 2025
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

Net income-17,609,413USD · FY 2025
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

Operating income-21,438,295USD · FY 2025
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

Diluted EPS-0.3USD per share · FY 2025
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

Some figures are unavailable for this reporting year.

balance sheet · annual statements
Line itemQ2 2025Q2 2024Q2 2023FY 2025FY 2024FY 2023FY 2022
ASSETS
AssetsUSD66,516,743
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

100,779,599
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—78,263,297
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

89,268,425
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

115,728,838
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

152,399,845
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Property, Plant and Equipment, NetUSD901,383
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

1,439,102
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—717,374
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

1,125,389
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

1,835,121
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

2,782,963
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Current assets:
Cash and Cash Equivalents, at Carrying ValueUSD62,828,156
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

95,673,787
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—74,523,782
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

85,194,502
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

109,934,257
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

143,758,678
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Assets, CurrentUSD65,363,364
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

98,804,568
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—77,375,165
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

87,778,005
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

113,443,729
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

149,315,433
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Prepaid Expense and Other Assets, CurrentUSD2,532,759
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

3,099,362
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—2,834,034
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

2,575,194
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

3,287,445
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

4,937,323
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Operating Lease, Right-of-Use AssetUSD214,556
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

254,048
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—145,535
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

283,645
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

365,103
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

191,877
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Other Assets, NoncurrentUSD37,440
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

281,881
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—25,223
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

81,386
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

84,885
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

109,572
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

LIABILITIES AND EQUITY
LiabilitiesUSD28,604,954
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

44,192,011
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—26,363,750
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

38,744,581
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

45,169,341
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

69,309,495
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Stockholders’ equity:
Common Stock, Value, IssuedUSD5,891
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

5,554
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—5,923
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

5,889
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

5,547
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

5,497
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Additional Paid in CapitalUSD364,254,280
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

352,645,033
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—366,043,455
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

362,220,445
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

350,105,518
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

342,739,268
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Retained Earnings (Accumulated Deficit)USD-324,652,827
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

-294,763,192
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—-328,785,000
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

-311,175,587
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

-277,751,476
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

-258,805,106
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Accumulated Other Comprehensive Income (Loss), Net of TaxUSD-1,695,555
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

-1,299,803
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—-1,914,831
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

-526,903
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

-1,800,088
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

-849,305
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Stockholders' Equity Attributable to ParentUSD37,911,789
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

56,587,588
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2024-06-30

82,793,528
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2023-06-30

35,349,547
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

50,523,844
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

70,559,497
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

83,090,350
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Liabilities and EquityUSD66,516,743
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

100,779,599
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—78,263,297
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

89,268,425
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

115,728,838
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

152,399,845
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Current liabilities:
Liabilities, CurrentUSD28,516,249
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

39,517,674
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—25,172,096
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

38,184,938
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

31,455,647
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

55,080,402
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Operating Lease, Liability, CurrentUSD125,851
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

141,281
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—92,055
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

141,341
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

195,955
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

151,983
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Accounts Payable, CurrentUSD3,626,223
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

3,370,641
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—2,884,507
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

4,241,773
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

3,093,752
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

3,666,124
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Operating Lease, Liability, NoncurrentUSD88,705
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

114,086
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—53,480
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

142,304
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

173,660
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

53,834
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Other Liabilities, NoncurrentUSD——————28,718
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Additional Financial Items
Long-term Debt, Current MaturitiesUSD4,539,994
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

11,765,449
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—711,359
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

12,923,599
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

4,161,549
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

2,850,128
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Long-term Debt, Excluding Current MaturitiesUSD—4,560,251
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—1,138,174
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

417,339
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

13,540,034
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

14,146,541
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Short-term InvestmentsUSD0
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

0
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2024-06-30

—0
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

0
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

——

Lines labelled “Derived” are calculated from reported figures.

cash flow · annual statements
Line itemQ2 2025Q2 2024Q2 2023FY 2025FY 2024FY 2023FY 2022
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD———-17,609,413
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

-33,424,111
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

-18,946,370
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

-79,971,847
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, Depletion and AmortizationUSD———438,864
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

722,950
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

980,053
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

1,145,995
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Share-based Payment Arrangement, Noncash ExpenseUSD———3,741,548
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

4,909,573
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

7,271,700
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

10,520,282
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Changes in operating assets and liabilities:
Increase (Decrease) in Accounts ReceivableUSD——————-3,000,000
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Increase (Decrease) in Accounts PayableUSD———-1,357,266
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

1,148,021
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

-572,372
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

344,509
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Deferred Income Tax Expense (Benefit)USD——————-44,163
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Net Cash Provided by (Used in) Operating ActivitiesUSD———-15,657,450
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

-29,700,985
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

-28,454,839
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

-48,611,687
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Cash flows from investing activities:
Net Cash Provided by (Used in) Investing ActivitiesUSD———476,803
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

1,110,127
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

-77,356
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

-686,046
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Cash flows from financing activities:
Payments for Repurchase of Common StockUSD——————3,976,681
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Net Cash Provided by (Used in) Financing ActivitiesUSD———4,445,374
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

3,769,220
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

-5,366,946
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

17,822,973
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD———-10,670,720
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

-24,739,755
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

-33,824,421
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

-30,632,565
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD62,828,156
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2025-06-30

95,673,787
Source

6-K · 2025-08-12 · 0001410578-25-001700

As of 2024-06-30

128,759,962
Source

6-K · 2024-07-25 · 0001410578-24-001109

As of 2023-06-30

74,523,782
Source

20-F · 2026-04-01 · 0001104659-26-038612

As of 2025-12-31

85,194,502
Source

20-F · 2025-03-24 · 0001410578-25-000419

As of 2024-12-31

109,934,257
Source

20-F · 2024-03-29 · 0001104659-24-041109

As of 2023-12-31

143,758,678
Source

20-F · 2023-04-28 · 0001104659-23-052043

As of 2022-12-31

Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD———402,956
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

778,513
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

1,047,717
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

603,680
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Income Taxes Paid, NetUSD———1,602
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

33,947
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

1,376,856
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

2,433,241
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Additional Financial Items
Share-based Payment Arrangement, ExpenseUSD———3,741,548
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

4,909,573
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

7,271,700
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

10,520,282
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Foreign Currency Transaction Gain (Loss), before TaxUSD———1,318,235
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

-906,212
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

1,446,202
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

2,555,325
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

General and Administrative ExpenseUSD———7,075,624
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

7,273,335
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

8,672,843
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

11,873,867
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Income Tax Expense (Benefit)USD———-297,860
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

-17,553
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

1,691,408
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

459,055
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

InterestExpenseNonoperatingUSD———463,132
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

851,874
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

——
Investment Income, InterestUSD———2,303,990
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

3,801,345
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

——
Net Income (Loss) Attributable to ParentUSD———-17,609,413
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

-33,424,111
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

-18,946,370
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

-79,971,847
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Net Income (Loss) Available to Common Stockholders, BasicUSD———-17,609,413
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

-33,424,111
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

-18,946,370
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

-79,971,847
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Proceeds from Issuance of Common StockUSD————7,331,019
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

——
Proceeds from Stock Options ExercisedUSD———138,279
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

178,254
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

5,500
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

323,212
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemFY 2025FY 2024FY 2023FY 2022
Total RevenueUSD7,670,902
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

103,204
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

18,111,491
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

9,292,724
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Operating Income (Loss)USD-21,438,295
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

-35,951,543
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

-23,719,866
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

-83,920,683
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD-17,907,273
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

-33,441,664
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

-17,254,962
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

-79,512,792
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Income Tax Expense (Benefit)USD-297,860
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

-17,553
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

1,691,408
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

459,055
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Net Income (Loss) Attributable to ParentUSD-17,609,413
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

-33,424,111
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

-18,946,370
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

-79,971,847
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Earnings Per Share, BasicUSD per share-0.3
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

-0.59
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

-0.35
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

-1.48
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Earnings Per Share, DilutedUSD per share-0.3
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

-0.59
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

-0.35
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

-1.48
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Weighted Average Number of Shares Outstanding, Basicshares59,006,129
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

56,287,903
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

54,737,530
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

54,135,084
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Weighted Average Number of Shares Outstanding, Dilutedshares59,006,129
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

56,287,903
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

54,737,530
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

54,135,084
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Interest Expense (non-operating)USD463,132
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

851,874
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

——
Additional Financial Items
Current Income Tax Expense (Benefit)USD-297,860
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

-17,553
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

1,691,408
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

503,218
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Foreign Currency Transaction Gain (Loss), before TaxUSD1,318,235
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

-906,212
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

1,446,202
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

2,555,325
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

General and Administrative ExpenseUSD7,075,624
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

7,273,335
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

8,672,843
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

11,873,867
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD-1,630,999
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

———
Interest ExpenseUSD——1,107,820
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

693,323
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Investment Income, InterestUSD2,303,990
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

3,801,345
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

——
Net Income (Loss) Available to Common Stockholders, BasicUSD-17,609,413
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

-33,424,111
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

-18,946,370
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

-79,971,847
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Other Operating IncomeUSD——3,480,632
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

—
Research and Development ExpenseUSD22,033,573
Source

20-F · 2026-04-01 · 0001104659-26-038612

2025-01-01 to 2025-12-31

28,781,412
Source

20-F · 2025-03-24 · 0001410578-25-000419

2024-01-01 to 2024-12-31

36,639,146
Source

20-F · 2024-03-29 · 0001104659-24-041109

2023-01-01 to 2023-12-31

81,339,540
Source

20-F · 2023-04-28 · 0001104659-23-052043

2022-01-01 to 2022-12-31

Lines labelled “Derived” are calculated from reported figures.

Filing attachments

tm2630014d1_ex99-1.htm · 6-K · 2026-11-19

Exhibit 99.1 Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2×CD3 Double-Masked Bispecific T-Cell Engager First-in-human study will enroll patients with HER2-positive advanced solid tumors ADG138 design includes proprietary IgG1-based heterodimeric format and SAFEbody® double masking to support prolonged circulation and tumor-selective accumulation and activation SAN DIEGO, Calif. November 19, 2026 - Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, cl…

6-K · 2026-11-19 · 0001104659-26-129932

Read attachment ↗
tm2629877d1_ex99-1.htm · 6-K · 2026-11-17

Exhibit 99.1 Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer Study designed by medical oncologist to accelerate lifesaving care to patients SAN DIEGO, Calif., and LOS ANGELES, Calif., November 17, 2026 - Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, and City of Hope, one of the largest and most advan…

6-K · 2026-11-17 · 0001104659-26-128842

Read attachment ↗
tm2629316d1_ex99-1.htm · 6-K · 2026-11-09

Exhibit 99.1 Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA ® (pembrolizumab) in Microsatellite Stable Colorectal Cancer - Enrollment of 60 patients complete; initial results expected in 1H 2027 to inform dose regimen for the Phase 3 trial - Adagene continues to own worldwide commercial rights to muzastotug SAN DIEGO and SUZHOU, China, November 9, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG), a platf…

6-K · 2026-11-09 · 0001104659-26-124143

Read attachment ↗
tm2625845d1_ex99-1.htm · 6-K · 2026-09-22

Exhibit 99.1 Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary SAFEbody® precision masking technology on both HER2 and CD3 binding sites to enable tumor-selective therapy with low systemic toxicity Preclin…

6-K · 2026-09-22 · 0001104659-26-109485

Read attachment ↗
tm2624950d1_ex99-1.htm · 6-K · 2026-09-10

Exhibit 99.1 Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO, Calif., SUZHOU, China, September 10, 2026 - Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of n…

6-K · 2026-09-10 · 0001104659-26-106554

Read attachment ↗
tm2624926d1_ex99-1.htm · 6-K · 2026-09-09

Exhibit 99.1 Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody ® Antibody-Drug Conjugate Candidates SAN DIEGO and SUZHOU, China, September 9, 2026 - Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. (“Exelixis”). The m…

6-K · 2026-09-09 · 0001104659-26-106137

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.